{"entity":{"id":"nct06640049","kind":"trial","name":"A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China","aka":[],"tldr":"A phase 2 trial of Dostarlimab in colorectal cancer, run by GlaxoSmithKline, active and no longer recruiting.","summary":"A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China is a phase 2 interventional study registered as NCT06640049 by GlaxoSmithKline, with 23 participants enrolled, started 2024-10-17 and due to reach its primary completion in 2027-10-24. Interventions recorded: Dostarlimab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06640049","url":"https://clinicaltrials.gov/study/NCT06640049"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["dostarlimab"],"companies":["gsk"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06640049","phase":"2","setting":"A Phase 2, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer in China","sponsor":"GlaxoSmithKline","enrolled":23,"outcomes":[]},"route":"/trials/nct06640049/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}]}}